Clin2
NCT04573231Possibly a fitRecruiting

PET scan using PSMA for AR-positive metastatic breast cancer

Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer

Treatments studied

Part of Cancer, Skin clinical trials.

This Phase 2 study looks at using a special PET/CT scan tracer called PSMA to find signals in metastatic breast cancer that has high androgen receptor (AR) activity. It may help researchers better measure and target this type of cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
13 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have metastatic breast cancer that is HER2-negative
  • Your tumor tests show AR (androgen receptor) is at least 10%
  • You do not have an active cancer other than breast cancer (past cancers in remission may be okay)
  • You can safely lie flat for the scan and tolerate PET/CT
  • If you can become pregnant: you must not be pregnant or breastfeeding, and your pregnancy test must be negative within 7 days before the PET/CT

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06067503Recruiting· Phase 2
PET scan to detect hormone therapy resistance in breast cancer

This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.

Madison, Wisconsin
NCT06916637Recruiting
PET Imaging Study for HER2-Positive Breast Cancer

This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.

Qingdao, Shandong
NCT06909604Recruiting
PET scan for HER2 breast cancer during treatment

This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.

Beijing
NCT06586047Recruiting· Early Phase 1
PSMA PET scan for triple-negative breast cancer

This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.

Iowa City, Iowa
NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy

This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.

Chicago, Illinois
NCT06690970Recruiting
PSMA PET/CT scan for people with or suspected to have cancer

This study is looking at how well a special type of PET/CT scan (called PSMA PET/CT) can see cancer in people who have or may have certain tumors. It may help doctors better understand and track the disease.

Hefei, Anhui

Hear when a new Breast cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.